The Oncology Institute Q1 2026 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy TOI?
Source: seekingalpha
- Strong Financial Performance: In Q1 2026, The Oncology Institute (TOI) reported total revenue of $147.4 million, reflecting a 41% year-over-year growth, which underscores the company's ongoing expansion in value-based contracts and ancillary services, particularly in its pharmacy business, thereby solidifying its market position.
- Upgraded Cash Flow Projections: Management has raised its free cash flow expectations for 2026 to a range of $5 million to $15 million, indicating successful negotiations with key suppliers, which enhances the company's financial flexibility and capacity for future investments.
- Profitability in Florida Market: TOI has achieved profitability in Florida, with plans to cover approximately 200,000 Medicare Advantage members across 25 counties by Q3, marking a successful expansion and penetration in this critical market.
- Adjusted EBITDA Guidance: The CFO reiterated the adjusted EBITDA outlook for 2026 at $0 to $9 million, acknowledging potential seasonal challenges in Q2, yet maintaining an optimistic overall outlook that reflects the company's confidence in future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TOI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TOI
Wall Street analysts forecast TOI stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.000
Low
5.00
Averages
6.67
High
8.00
Current: 4.000
Low
5.00
Averages
6.67
High
8.00
About TOI
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
The Oncology Institute Q1 2026 Earnings Call Highlights
- Strong Financial Performance: In Q1 2026, The Oncology Institute (TOI) reported total revenue of $147.4 million, reflecting a 41% year-over-year growth, which underscores the company's ongoing expansion in value-based contracts and ancillary services, particularly in its pharmacy business, thereby solidifying its market position.
- Upgraded Cash Flow Projections: Management has raised its free cash flow expectations for 2026 to a range of $5 million to $15 million, indicating successful negotiations with key suppliers, which enhances the company's financial flexibility and capacity for future investments.
- Profitability in Florida Market: TOI has achieved profitability in Florida, with plans to cover approximately 200,000 Medicare Advantage members across 25 counties by Q3, marking a successful expansion and penetration in this critical market.
- Adjusted EBITDA Guidance: The CFO reiterated the adjusted EBITDA outlook for 2026 at $0 to $9 million, acknowledging potential seasonal challenges in Q2, yet maintaining an optimistic overall outlook that reflects the company's confidence in future growth.
See More
The Oncology Institute to Release Q1 2026 Financial Results
- Earnings Release Schedule: The Oncology Institute plans to announce its Q1 2026 financial results on May 7, 2026, followed by a conference call at 5:30 PM (Eastern Time), aimed at providing investors with the latest financial status and business developments.
- Conference Call Access: Investors can join the call by dialing 1-800-225-9448 (U.S.) or 1-203-518-9708 (international), with a replay available two hours post-call until May 21, 2026, ensuring timely access to critical information for stakeholders.
- Webcast Option: In addition to the phone call, investors can listen to a simultaneous webcast of the conference call via the Investor Relations section of the company’s website, enhancing information accessibility and transparency, reflecting the company's commitment to investor communication.
- Company Background: Founded in 2007, The Oncology Institute is dedicated to delivering value-based cancer care in community settings, serving approximately 1.9 million patients with over 180 clinicians and 100 clinics, showcasing its expertise and impact in the oncology field.
See More
Topicus, Lumine, and Constellation Shareholder Meetings Scheduled
- Meeting Schedule: The annual shareholder meetings for Topicus, Lumine Group, and Constellation Software are set for May 15, 2026, at 8:00, 8:15, and 8:30 AM respectively, utilizing a hybrid format to accommodate both in-person and virtual attendance.
- Registration Requirement: Attendees are required to register online by May 8, 2026, to assist in tracking in-person attendance, ensuring smooth proceedings, with registration links available on each company's website.
- Q&A Session: A joint Q&A session will follow the meetings at 9:00 AM, allowing shareholders to participate either in person or virtually, with the option to submit questions in advance to enhance engagement.
- Technical Support: Shareholders must ensure they have internet-connected devices to participate in virtual meetings, with detailed participation instructions and proxy appointment guidelines provided on the respective company websites to facilitate smooth attendance.
See More
The Oncology Institute to Participate in Healthcare Conference
- Executive Participation: The Oncology Institute's CEO Daniel Virnich and CFO Rob Carter will participate in the 25th Annual Needham Healthcare Conference on April 15, 2026, showcasing the company's leadership in oncology care.
- Virtual Conference Format: The event will be held virtually, featuring a fireside chat at 3:45 p.m. ET, aimed at sharing the company's latest developments and strategic insights with investors.
- Investor Relations Access: A webcast link will be available on the company's Investor Relations website, ensuring that investors can access the conference content in real-time, enhancing transparency and engagement.
- Company Overview: Founded in 2007, The Oncology Institute provides value-based cancer care to approximately 1.9 million patients, employing over 180 clinicians and operating more than 100 clinics, demonstrating significant market influence.
See More
Oncology Institute Reports First Profitable Quarter and Strong Growth in 2025
- First Profitability Milestone: The Oncology Institute (TOI) achieved positive adjusted EBITDA in Q4 2025, marking its first profitable quarter as a public company, with expectations to maintain positive EBITDA in 2026, showcasing the sustainability and profitability of its business model.
- Significant Revenue Growth: In 2025, TOI's total revenue increased approximately 28% year-over-year, surpassing $500 million for the first time, primarily driven by the initiation of nine new capitated contracts, adding 260,000 patients and further solidifying its market position.
- Strong Pharmacy Performance: TOI's pharmacy revenue grew by 49.6% in 2025, reaching $269 million, contributing nearly $50 million in gross profit, reflecting its importance in the integrated care model and the rising market demand.
- Strategic Expansion and Leadership Enhancement: TOI strengthened its leadership team in 2025 with the addition of a Chief Clinical Officer and Chief Administrative Officer, expected to drive further market expansion and growth strategy, particularly in the capitated model in Florida for greater success.
See More
The Oncology Institute Reports Significant Revenue Growth in 2025 Financial Results
- Significant Revenue Growth: In Q4 2025, The Oncology Institute reported revenue of $142 million, a 41.6% increase from $100.3 million in Q4 2024, indicating strong market demand for its healthcare services and enhancing financial stability.
- Gross Profit Improvement: The company's gross profit rose 55.2% to $22.7 million in Q4, compared to $15 million a year earlier, reflecting improved operational efficiency and cost control capabilities.
- Narrowed Net Loss: The net loss for Q4 2025 was reduced to $7.5 million, or $0.06 per share, down from $13.2 million and $0.14 per share in the prior year, demonstrating positive progress in profitability.
- Optimistic Future Outlook: The Oncology Institute expects 2026 revenue between $630 million and $650 million, with gross profit projected between $97 million and $107 million, as management reaffirms its goal of achieving positive full-year Adjusted EBITDA in 2026, indicating substantial growth potential ahead.
See More
The Oncology Institute Q1 2026 Earnings Call Highlights
- Strong Financial Performance: In Q1 2026, The Oncology Institute (TOI) reported total revenue of $147.4 million, reflecting a 41% year-over-year growth, which underscores the company's ongoing expansion in value-based contracts and ancillary services, particularly in its pharmacy business, thereby solidifying its market position.
- Upgraded Cash Flow Projections: Management has raised its free cash flow expectations for 2026 to a range of $5 million to $15 million, indicating successful negotiations with key suppliers, which enhances the company's financial flexibility and capacity for future investments.
- Profitability in Florida Market: TOI has achieved profitability in Florida, with plans to cover approximately 200,000 Medicare Advantage members across 25 counties by Q3, marking a successful expansion and penetration in this critical market.
- Adjusted EBITDA Guidance: The CFO reiterated the adjusted EBITDA outlook for 2026 at $0 to $9 million, acknowledging potential seasonal challenges in Q2, yet maintaining an optimistic overall outlook that reflects the company's confidence in future growth.
See More
The Oncology Institute to Release Q1 2026 Financial Results
- Earnings Release Schedule: The Oncology Institute plans to announce its Q1 2026 financial results on May 7, 2026, followed by a conference call at 5:30 PM (Eastern Time), aimed at providing investors with the latest financial status and business developments.
- Conference Call Access: Investors can join the call by dialing 1-800-225-9448 (U.S.) or 1-203-518-9708 (international), with a replay available two hours post-call until May 21, 2026, ensuring timely access to critical information for stakeholders.
- Webcast Option: In addition to the phone call, investors can listen to a simultaneous webcast of the conference call via the Investor Relations section of the company’s website, enhancing information accessibility and transparency, reflecting the company's commitment to investor communication.
- Company Background: Founded in 2007, The Oncology Institute is dedicated to delivering value-based cancer care in community settings, serving approximately 1.9 million patients with over 180 clinicians and 100 clinics, showcasing its expertise and impact in the oncology field.
See More
Topicus, Lumine, and Constellation Shareholder Meetings Scheduled
- Meeting Schedule: The annual shareholder meetings for Topicus, Lumine Group, and Constellation Software are set for May 15, 2026, at 8:00, 8:15, and 8:30 AM respectively, utilizing a hybrid format to accommodate both in-person and virtual attendance.
- Registration Requirement: Attendees are required to register online by May 8, 2026, to assist in tracking in-person attendance, ensuring smooth proceedings, with registration links available on each company's website.
- Q&A Session: A joint Q&A session will follow the meetings at 9:00 AM, allowing shareholders to participate either in person or virtually, with the option to submit questions in advance to enhance engagement.
- Technical Support: Shareholders must ensure they have internet-connected devices to participate in virtual meetings, with detailed participation instructions and proxy appointment guidelines provided on the respective company websites to facilitate smooth attendance.
See More
The Oncology Institute to Participate in Healthcare Conference
- Executive Participation: The Oncology Institute's CEO Daniel Virnich and CFO Rob Carter will participate in the 25th Annual Needham Healthcare Conference on April 15, 2026, showcasing the company's leadership in oncology care.
- Virtual Conference Format: The event will be held virtually, featuring a fireside chat at 3:45 p.m. ET, aimed at sharing the company's latest developments and strategic insights with investors.
- Investor Relations Access: A webcast link will be available on the company's Investor Relations website, ensuring that investors can access the conference content in real-time, enhancing transparency and engagement.
- Company Overview: Founded in 2007, The Oncology Institute provides value-based cancer care to approximately 1.9 million patients, employing over 180 clinicians and operating more than 100 clinics, demonstrating significant market influence.
See More
Oncology Institute Reports First Profitable Quarter and Strong Growth in 2025
- First Profitability Milestone: The Oncology Institute (TOI) achieved positive adjusted EBITDA in Q4 2025, marking its first profitable quarter as a public company, with expectations to maintain positive EBITDA in 2026, showcasing the sustainability and profitability of its business model.
- Significant Revenue Growth: In 2025, TOI's total revenue increased approximately 28% year-over-year, surpassing $500 million for the first time, primarily driven by the initiation of nine new capitated contracts, adding 260,000 patients and further solidifying its market position.
- Strong Pharmacy Performance: TOI's pharmacy revenue grew by 49.6% in 2025, reaching $269 million, contributing nearly $50 million in gross profit, reflecting its importance in the integrated care model and the rising market demand.
- Strategic Expansion and Leadership Enhancement: TOI strengthened its leadership team in 2025 with the addition of a Chief Clinical Officer and Chief Administrative Officer, expected to drive further market expansion and growth strategy, particularly in the capitated model in Florida for greater success.
See More
The Oncology Institute Reports Significant Revenue Growth in 2025 Financial Results
- Significant Revenue Growth: In Q4 2025, The Oncology Institute reported revenue of $142 million, a 41.6% increase from $100.3 million in Q4 2024, indicating strong market demand for its healthcare services and enhancing financial stability.
- Gross Profit Improvement: The company's gross profit rose 55.2% to $22.7 million in Q4, compared to $15 million a year earlier, reflecting improved operational efficiency and cost control capabilities.
- Narrowed Net Loss: The net loss for Q4 2025 was reduced to $7.5 million, or $0.06 per share, down from $13.2 million and $0.14 per share in the prior year, demonstrating positive progress in profitability.
- Optimistic Future Outlook: The Oncology Institute expects 2026 revenue between $630 million and $650 million, with gross profit projected between $97 million and $107 million, as management reaffirms its goal of achieving positive full-year Adjusted EBITDA in 2026, indicating substantial growth potential ahead.
See More
